R Hassan

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Nonpleural mesotheliomas: mesothelioma of the peritoneum, tunica vaginalis, and pericardium
    Raffit Hassan
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Room 5116, Bethesda, MD 20892 4264, USA
    Hematol Oncol Clin North Am 19:1067-87, vi. 2005
  2. ncbi request reprint Loss of mesothelin expression by mesothelioma cells grown in vitro determines sensitivity to anti-mesothelin immunotoxin SS1P
    Jingli Zhang
    Laboratory of Molecular Biology, National Cancer Institute, 37 Convent Drive, Room 5116, Bethesda, MD 20892 4264, USA
    Anticancer Res 32:5151-8. 2012
  3. pmc Mesothelin-targeted agents in clinical trials and in preclinical development
    Ronan J Kelly
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Mol Cancer Ther 11:517-25. 2012
  4. ncbi request reprint Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer
    Raffit Hassan
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute NIH, 37 Convent Drive, Bethesda, MD 20892, USA
    Clin Cancer Res 12:447-53. 2006
  5. ncbi request reprint Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference
    R Hassan
    National Cancer Institute, National Institutes of Health, 37 Convent Drive, Room 5116, Bethesda, MD 20892 4264 USA
    Ann Oncol 17:1615-9. 2006
  6. ncbi request reprint Tumor-directed radiation and the immunotoxin SS1P in the treatment of mesothelin-expressing tumor xenografts
    Raffit Hassan
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA
    Clin Cancer Res 12:4983-8. 2006
  7. pmc Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy
    Raffit Hassan
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 4264, USA
    Lung Cancer 68:455-9. 2010
  8. ncbi request reprint Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers
    Raffit Hassan
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute and Clinical Center, NIH, Bethesda, Maryland 20892 4264, USA
    Clin Cancer Res 13:5144-9. 2007
  9. pmc Mesothelin targeted cancer immunotherapy
    Raffit Hassan
    Solid Tumor Immunotherapy Section, Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892 4264, USA
    Eur J Cancer 44:46-53. 2008
  10. pmc Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers
    Raffit Hassan
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 4264, USA
    Clin Cancer Res 16:6132-8. 2010

Collaborators

Detail Information

Publications40

  1. ncbi request reprint Nonpleural mesotheliomas: mesothelioma of the peritoneum, tunica vaginalis, and pericardium
    Raffit Hassan
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Room 5116, Bethesda, MD 20892 4264, USA
    Hematol Oncol Clin North Am 19:1067-87, vi. 2005
    ..Given the rarity of these tumors, it is difficult to obtain precise information regarding their incidence, natural history, and optimal management...
  2. ncbi request reprint Loss of mesothelin expression by mesothelioma cells grown in vitro determines sensitivity to anti-mesothelin immunotoxin SS1P
    Jingli Zhang
    Laboratory of Molecular Biology, National Cancer Institute, 37 Convent Drive, Room 5116, Bethesda, MD 20892 4264, USA
    Anticancer Res 32:5151-8. 2012
    ..To determine if early passage tumor cells obtained from patients with mesothelioma continue to express the tumor differentiation antigen mesothelin and their sensitivity to the anti-mesothelin immunotoxin SS1P...
  3. pmc Mesothelin-targeted agents in clinical trials and in preclinical development
    Ronan J Kelly
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Mol Cancer Ther 11:517-25. 2012
    ..This review highlights ongoing clinical trials, as well as other approaches to exploit mesothelin for cancer therapy, that are in preclinical development...
  4. ncbi request reprint Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer
    Raffit Hassan
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute NIH, 37 Convent Drive, Bethesda, MD 20892, USA
    Clin Cancer Res 12:447-53. 2006
    ..To determine whether mesothelin, a cell surface protein highly expressed in mesothelioma and ovarian cancer, is shed into serum and if so to accurately measure it...
  5. ncbi request reprint Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference
    R Hassan
    National Cancer Institute, National Institutes of Health, 37 Convent Drive, Room 5116, Bethesda, MD 20892 4264 USA
    Ann Oncol 17:1615-9. 2006
    ..This report summarizes the proceedings of the meeting as well as directions for future clinical and basic research...
  6. ncbi request reprint Tumor-directed radiation and the immunotoxin SS1P in the treatment of mesothelin-expressing tumor xenografts
    Raffit Hassan
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA
    Clin Cancer Res 12:4983-8. 2006
    ..The goal of this study was to determine if radiation therapy in combination with the antimesothelin immunotoxin SS1(dsFv)PE38 (SS1P) would result in enhanced antitumor activity against mesothelin-expressing xenografts in nude mice...
  7. pmc Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy
    Raffit Hassan
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 4264, USA
    Lung Cancer 68:455-9. 2010
    ..MORAb-009 is a chimeric anti-mesothelin monoclonal antibody...
  8. ncbi request reprint Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers
    Raffit Hassan
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute and Clinical Center, NIH, Bethesda, Maryland 20892 4264, USA
    Clin Cancer Res 13:5144-9. 2007
    ..To determine the toxicities, maximum tolerated dose (MTD) and pharmacokinetics of the recombinant immunotoxin SS1P (anti-mesothelin dsFv-PE38) in patients with mesothelin-expressing cancers...
  9. pmc Mesothelin targeted cancer immunotherapy
    Raffit Hassan
    Solid Tumor Immunotherapy Section, Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892 4264, USA
    Eur J Cancer 44:46-53. 2008
    ..These ongoing clinical trials will help define the utility of mesothelin as a target for cancer therapy...
  10. pmc Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers
    Raffit Hassan
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 4264, USA
    Clin Cancer Res 16:6132-8. 2010
    ..5 to 400 mg/m(2). Disease evaluation with computed tomography occurred on day 35. Subjects with responding or stable disease could receive additional cycles of MORAb-009...
  11. ncbi request reprint Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts
    Raffit Hassan
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, and the Clinical Center, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 13:7166-71. 2007
    ..To determine the antitumor activity of the anti-mesothelin immunotoxin SS1P in combination with gemcitabine against mesothelin-expressing tumor xenografts...
  12. ncbi request reprint Mesothelin: a new target for immunotherapy
    Raffit Hassan
    Laboratory of Molecular Biology, National Cancer Institute, NIH, Bethesda, Maryland, USA
    Clin Cancer Res 10:3937-42. 2004
    ..There is evidence that mesothelin is an immunogenic protein and could be exploited as a therapeutic cancer vaccine. A soluble mesothelin variant has been identified and could be a useful tumor marker for malignant mesotheliomas...
  13. ncbi request reprint Acute myeloid leukemia following treatment with cladribine for hairy cell leukemia: a case report and review of the literature
    R Hassan
    Department of Medicine Hematology Oncology Section, University of Oklahoma Health Sciences Center, Oklahoma City, USA
    Leuk Lymphoma 45:2149-52. 2004
    ..2 years) after the diagnosis and treatment of HCL. Further studies are needed to clarify whether leukemias seen in patients following the treatment of their HCL are incidental findings or related to HCL and its treatments...
  14. ncbi request reprint Localization of mesothelin in epithelial ovarian cancer
    Raffit Hassan
    Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 4264, USA
    Appl Immunohistochem Mol Morphol 13:243-7. 2005
    ..Patients whose tumors express mesothelin could be eligible for participation in clinical trials of novel agents targeting mesothelin...
  15. ncbi request reprint Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1
    Raffit Hassan
    Laboratory of Molecular Biology, National Cancer Institute, NIH, Bethesda, Maryland, USA
    Clin Cancer Res 10:16-8. 2004
    ..The development of human antibodies against LMB-1 was detected using a serum neutralization and ELISA...
  16. pmc A binding domain on mesothelin for CA125/MUC16
    Osamu Kaneko
    Laboratory of Molecular Biology, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Biol Chem 284:3739-49. 2009
    ..The identified CA125-binding domain significantly inhibits cancer cell adhesion and merits evaluation as a new therapeutic agent for preventing or treating peritoneal malignant tumors...
  17. ncbi request reprint Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients
    Mitchell Ho
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA
    Clin Cancer Res 11:3814-20. 2005
    ..Here we addressed the issue of whether mesothelin elicits a humoral immune response in patients with mesothelioma and ovarian cancer...
  18. pmc Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors
    Yujian Zhang
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
    Proc Natl Acad Sci U S A 104:17099-104. 2007
    ....
  19. ncbi request reprint Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients
    Masanori Onda
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Bethesda, MD 20892, USA
    J Immunol 177:8822-34. 2006
    ..Our results indicate that a relatively small number of discrete immunogenic sites are associated with PE38, most of which can be eliminated by point mutations...
  20. ncbi request reprint Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice
    Yujian Zhang
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892 4264, USA
    Clin Cancer Res 12:4695-701. 2006
    ..Established tumors were treated i.v. with immunotoxin SS1P alone, i.p. with Taxol alone, or with the two agents together. SS1P was radiolabeled with (111)In and used to study the effect of Taxol on its uptake by A431/K5 tumors...
  21. ncbi request reprint Cytotoxic activity of the recombinant anti-mesothelin immunotoxin, SS1(dsFv)PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomas
    Qian Li
    Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
    Anticancer Res 24:1327-35. 2004
    ....
  22. ncbi request reprint Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma
    Masanori Onda
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 4264, USA
    Clin Cancer Res 12:4225-31. 2006
    ..To establish monoclonal antibodies (mAb) against megakaryocyte potentiation factor (MPF) and detect MPF in the blood of patients with mesothelioma...
  23. ncbi request reprint Pretargeted radioimmunotherapy of mesothelin-expressing cancer using a tetravalent single-chain Fv-streptavidin fusion protein
    Noriko Sato
    Nuclear Medicine Department, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Nucl Med 46:1201-9. 2005
    ..We evaluated the biodistribution and tumor-targeting ability of an antimesothelin tetravalent single-chain Fv-streptavidin fusion protein (SS1scFvSA) in mice...
  24. ncbi request reprint Immunotoxin treatment of cancer
    Ira Pastan
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Annu Rev Med 58:221-37. 2007
    ..Strategies to overcome these limitations are being pursued...
  25. pmc Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P
    Robert J Kreitman
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 4264, USA
    Clin Cancer Res 15:5274-9. 2009
    ..To conduct a phase I trial of recombinant immunotoxin SS1P given by continuous infusion in chemoresistant solid tumors expressing mesothelin...
  26. ncbi request reprint Releasable PEGylation of mesothelin targeted immunotoxin SS1P achieves single dosage complete regression of a human carcinoma in mice
    David Filpula
    Enzon Pharmaceuticals, Incorporated, 20 Kingsbridge Road, Piscataway, New Jersey 08854, and Laboratory of Molecular Biology, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Bioconjug Chem 18:773-84. 2007
    ..Since the bioconjugates can also exhibit the attributes of passive targeting via enhanced permeability and retention, this is the first demonstration of a pivotal role of active targeting for immunotoxin bioconjugate efficacy...
  27. ncbi request reprint Immunotoxin therapy of cancer
    Ira Pastan
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institues of Health, 37 Convent Drive, Bethesda, MD 20892 4264, USA
    Nat Rev Cancer 6:559-65. 2006
    ..Results from clinical trials indicate that recombinant immunotoxins and similar agents that are designed to combine antibody selectivity with toxin cell-killing potency will be useful additions to cancer therapy...
  28. pmc A flow cytometry method to quantitate internalized immunotoxins shows that taxol synergistically increases cellular immunotoxins uptake
    Yujian Zhang
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 4264, USA
    Cancer Res 70:1082-9. 2010
    ..Further, we suggest one basis to understand why chemotherapy and antibody-based therapies cooperate when combined in cancer treatment...
  29. ncbi request reprint New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISA
    Masanori Onda
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 4264, USA
    Clin Cancer Res 11:5840-6. 2005
    ..We have produced novel MAbs to mesothelin to help study mesothelin function and to develop improved diagnosis and immunotherapy of mesothelin-expressing tumors...
  30. pmc Identification of novel human CTL epitopes and their agonist epitopes of mesothelin
    Junko Yokokawa
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 11:6342-51. 2005
    ..The purpose of this study was to define novel mesothelin CTL epitopes and, more importantly, agonist epitopes that would more efficiently activate human T cells to more efficiently lyse human tumors...
  31. ncbi request reprint Effects of retinoids on cancerous phenotype and apoptosis in organotypic cultures of ovarian carcinoma
    S Guruswamy
    Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma City 73190, USA
    J Natl Cancer Inst 93:516-25. 2001
    ..93; P =.02). CONCLUSIONS: At clinically achievable concentrations, all retinoids tested decrease the growth fraction, induce differentiation and apoptosis. Induction of MUC1 expression is implicated in the mechanisms of action...
  32. doi request reprint Initial characterization of an immunotoxin constructed from domains II and III of cholera exotoxin
    Robert Sarnovsky
    Laboratory of Molecular Biology, CCR, NCI, NIH, HHS, Bethesda, MD 20892, USA
    Cancer Immunol Immunother 59:737-46. 2010
    ....
  33. ncbi request reprint Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro
    Raffit Hassan
    Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA
    Clin Cancer Res 8:3520-6. 2002
    ..The objective of this study was to determine the antitumor activity of SS1(dsFv)PE38, a recombinant antimesothelin immunotoxin, against human gynecologic tumors grown in short-term culture in vitro...
  34. ncbi request reprint Mesothelin expression in human lung cancer
    Mitchell Ho
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA
    Clin Cancer Res 13:1571-5. 2007
    ..To investigate mesothelin as a new target for immunotherapy in lung cancer...
  35. ncbi request reprint Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis
    Raffit Hassan
    Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 4264, USA
    Am J Clin Pathol 124:838-45. 2005
    ..Our results demonstrated mesothelin expression in the majority of pancreaticobiliary adenocarcinomas and no expression in normal pancreatic tissues and in chronic pancreatitis...
  36. doi request reprint Malignant mesothelioma of the inguinal canal with an unusually long survival
    Janice M Walshe
    National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 4264, USA
    Am J Clin Oncol 31:306-7. 2008
  37. ncbi request reprint Update on malignant mesothelioma
    Karen Antman
    Provost, Boston University Medical Campus Dean, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    Oncology (Williston Park) 19:1301-9; discussion 1309-10, 1313-6. 2005
    ..Recent randomized trials have shown significant improvement in time to progression and survival for the addition of new antifolates to platinum-based chemotherapy...
  38. pmc Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin
    Raffit Hassan
    Morphotek Inc, 210 Welsh Pool Road, Exton, PA, USA
    Cancer Immun 7:20. 2007
    ..We have in fact initiated a Phase I clinical study enrolling patients with mesothelin-positive pancreatic, mesothelioma, non-small cell lung and ovarian cancers...
  39. ncbi request reprint Mesothelin, a possible target for immunotherapy, is expressed in primary AML cells
    Daniel Steinbach
    University Children s Hospital Jena, Germany
    Eur J Haematol 79:281-6. 2007
    ..SS1(dsFv)PE38 is a recombinant anti-mesothelin immunotoxin which is undergoing clinical evaluation in patients with mesothelin-expressing tumors...
  40. ncbi request reprint Mesothelin is shed from tumor cells
    Mitchell Ho
    Cancer Epidemiol Biomarkers Prev 15:1751. 2006